Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » New Target for Huntington’s Disease Therapy
Disease Discoveries

New Target for Huntington’s Disease Therapy

By Nora DunneAug 13, 2014
Share
Facebook Twitter Email
A two-photon image shows a striatal neuron. The study showed that striatal neurons fail to respond to BDNF protein messages in an appropriate way. 

 

Northwestern Medicine scientists have discovered a new origin for the abnormal involuntary movements associated with Huntington’s disease.

Huntington’s disease is a neurodegenerative genetic disorder whose earliest pathology appears in the striatum, a region of the forebrain involved in the control of movement.

“The degeneration in Huntington’s disease was thought to be a consequence of impaired delivery of a survival signal to the striatum, causing it to wither and die,” said D. James Surmeier, PhD, chair of the Department of Physiology and senior investigator of the study. “We show that at least in the early stages of the disease, this isn’t the case. Rather, the problem stems from a misinterpretation of the survival signal.”

In the past, debilitating movements were attributed to the loss of a protein called the brain-derived neurotrophic factor (BDNF). Its delivery from the cerebral cortex to the striatum supposedly decreased in Huntington’s disease.

However, the scientists were surprised to find that in mice models with early Huntington’s disease, BDNF delivery was normal. Instead, they discovered that striatal neurons failed to respond to BDNF messages in an appropriate way.

Signaling of a protein called tyrosine-related kinase B (TrkBR) was impaired. Stopping a protein known to inhibit TrkBR signaling, called p75 neurotrophic receptor (p75NTR), corrects that problem.

Signaling impairments lead to degeneration in early Huntington’s disease patients, according to senior investigator D. James Surmeier, PhD, chair of the Department of Physiology. 

 

Joshua Plotkin, PhD, ’12 GME, research assistant professor in Physiology, was first author of the study. The findings, published in Neuron, have some immediate implications for the disease.

“This shows us what won’t work as a therapy in Huntington’s disease. This is not trivial because there has been a great deal of effort and money spent on replacing the survival signal,” said Surmeier. “Attempts to stem the brain degeneration in Huntington’s disease by giving a molecule that mimics BDNF will not succeed.”

Currently, there is no cure for Huntington’s disease, but this research may pave the way for one.

“The culprit in the miscommunication is another protein, p75NTR, that could be targeted with drugs or other strategies, like gene therapy,” said Surmeier. “Our work provides an alternative target that is likely to be a viable therapeutic strategy.”

This work was supported by the Cure Huntington’s Disease Initiative Foundation, the JPB Foundation, the Fisher Center for Alzheimer’s Research Foundation and NIH grants NS034696, MH074866 and NS067414.

Physiology Research
Share. Facebook Twitter Email

Related Posts

Fathers’ Presence During Childhood Predicts Adult Testosterone Levels

Jun 29, 2022

Epigenetic Biomarkers Predict CVD Risk

Jun 28, 2022

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Comments are closed.

Latest News

Fathers’ Presence During Childhood Predicts Adult Testosterone Levels

Jun 29, 2022

Epigenetic Biomarkers Predict CVD Risk

Jun 28, 2022

Student Spearheads Ukraine Aid Efforts

Jun 27, 2022

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Identifying Protein Interactions that Promote Cancer Growth

Jun 24, 2022
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20220617_NM_0434
20220617_NM_0858
20220617_NM_0643
20220617_NM_0835
20220617_NM_0544
20220617_NM_0450
20220617_NM_0790
20220617_NM_0811
20220617_NM_0851
20220617_NM_0696
20220617_NM_0779
20220617_NM_0838

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2022 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.